据悉，Rybelsus的研究于2019年开始，参与研究的患者接近1万名。诺和诺德表示，将在明年初左右寻求美国和欧洲监管机构批准更广泛地使用Rybelsus。Novo Nordisk's oral semaglutide (Rybelsus) has been shown to reduce the risk of heart attacks and strokes in a large study, which could lead to wider use of the drug.
Novo Nordisk said on Monday that the study showed that people with type 2 diabetes and pre-existing heart disease or chronic kidney disease, or those with all three conditions, had a 14% lower risk of developing cardiovascular disease after taking Rybelsus than those taking a placebo. The company stated that the side effects were consistent with previous studies.
Martin Holst Lange, head of drug development at Novo Nordisk, stated that the research results suggest that Rybelsus can even help patients already receiving standard treatment to reduce the risk of heart disease.
It is reported that the study on Rybelsus started in 2019, with nearly 0.01 million patients involved in the research. Novo Nordisk stated that they will seek approval from US and European regulatory agencies for broader use of Rybelsus around the beginning of next year.
